ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

OPTN OptiNose Inc

0.867
-0.038 (-4.20%)
Apr 26 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 3,147,264
Bid Price 0.8315
Ask Price 0.867
News -
Day High 0.9136

Low
0.80

52 Week Range

High
2.10

Day Low 0.80
Share Name Share Symbol Market Stock Type
OptiNose Inc OPTN NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.038 -4.20% 0.867 18:58:15
Open Price Low Price High Price Close Price Previous Close
0.8953 0.80 0.9136 0.8604 0.905
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
9,616 3,147,264 US$ 0.8453663 US$ 2,660,591 - 0.80 - 2.10
Last Trade Type Quantity Price Currency
18:52:24 formt 588 US$ 0.867 USD

OptiNose Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
95.75M 112.65M - 70.99M -35.48M -0.32 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

OptiNose News

Date Time Source News Article
4/25/202406:00GlobeNewswire Inc.Optinose Provides Corporate Update on XHANCE Launch and..
4/04/202415:01GlobeNewswire Inc.Optinose to Present at the Needham Virtual Healthcare..
3/15/202414:34GlobeNewswire Inc.XHANCE Approved by FDA as First and Only Medication..
3/08/202415:10Edgar (US Regulatory)Form 8-K - Current report
3/07/202415:32Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee..
3/07/202406:01Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K..
3/07/202406:00GlobeNewswire Inc.Optinose Reports Fourth Quarter and Full Year 2023 Financial..
3/07/202406:00Edgar (US Regulatory)Form 8-K - Current report
2/29/202415:40GlobeNewswire Inc.Optinose Announces Reporting Date for Fourth Quarter 2023..
2/29/202415:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
2/29/202415:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
2/29/202415:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No OPTN Message Board. Create One! See More Posts on OPTN Message Board See More Message Board Posts

Historical OPTN Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.93271.250.800.91310445,044,962-0.0657-7.04%
1 Month1.481.490.800.97335061,646,156-0.613-41.42%
3 Months1.252.100.801.321,019,041-0.383-30.64%
6 Months1.192.100.801.30637,966-0.323-27.14%
1 Year1.762.100.801.28562,348-0.893-50.74%
3 Years3.7354.300.801.88371,767-2.87-76.79%
5 Years9.4411.660.803.30364,023-8.57-90.82%

OptiNose Description

OptiNose Inc is a US-based specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. The lead product of the company, XHANCE nasal spray, utilizes a proprietary breath powered exhalation delivery system, to deliver a topically acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids. The pipeline products of the company include XHANCE, OPN-300, OPN-021, and AVP-825.

Your Recent History

Delayed Upgrade Clock